Testing whether molecular alterations of LC-NEC could be a classifier to distinguish them from NET G3, we found 72/87 LC-NEC having mutations in APC, TP53, KRAS or BRAF as compared to 6/29 NET G3 (P = 2.3 × 10−9). The gene discussed is APC; the disease is neuroendocrine carcinoma.